id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dti-1410	Imai, Toshimi; Akimoto, Tetsu; Ito, Chiharu; Masuda, Takahiro; Nagata, Daisuke	Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention	2015	3	.pdf	application/pdf	2422	139	45	A case of volume depletion and prerenal azote- mia that required rehydration and the withdrawal of angio- tensin-converting inhibitor and diuretic treatment was recently reported in a phase II trial of dapagliflozin.15 Not surprisingly, dapagliflozin was effective and well tolerated as an adequate therapeutic option for modulating the present patient’s level of glycemic control. The lack of longitudinal data regarding the gross daily urine output, as well as the amount of urinary excreted sodium after the commencement of oral dapagliflozin treatment in the previous studies, precludes us from evaluating the valid- ity of our findings.10–12 Nevertheless, List et al, demonstrated that the administration of dapagliflozin in treatment-naive patients with type 2 diabetes resulted in an increased urinary output of between 107 mL/day and 470 mL/day, equating to ~0.3–1.5 additional voids per day.1,17 This highlights the need for further investigation regarding the impact of the diuretic properties of this agent on the overall management of diabetic patients.9 Obviously, the accumulation of more experience with additional cases similar to ours requires continuous and careful attention, and such a strategy would aid in the estab- lishment of a novel approach to treating fluid retention as well as investigating the therapeutic impact of SGLT-2 inhibitors in diabetic patients with nephrotic syndrome.	cache/dti-1410.pdf	txt/dti-1410.txt